RLYB-211

N/A

Report date: 2024/11/29 16:57:20

Base Information

Drug NameRLYB-211
Drug Alias Nameanti-HPA-1a ImmunoglobulinNAITgamTromplateRLYB-211RLYB211
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Polyclonal antibodies
Mechanisms of ActionIntegrin beta-3 inhibitors
TargetsIntegrin beta-3
Therapy Area/IndicationsHemolysis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRallybio Llc
China Registration ClassN/A

Develop Information

Active CompaniesRallybio Llc
Inactive CompaniesN/A
Active IndicationsHemolysis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A